So now we get a label to script out amphetamines in mass to treat patients with binge-eating disorder. Okay, so I'm not a physician, but is hunger the trigger for binge-eating? We were not invited to coordinate the trial for this indication, but I'm betting many people, all of the sudden, had a Dx of [...]
What a business. Seriously. As a research guy, I'm wondering if we can send subjects to a LabCorp to draw study labs. This would certainly save money at the site level if a certified phlebotomist is not required. Just a note: I personally think Covance is the best study lab. Quintiles is a very close [...]
Are the Abbvie shares stuck in the mud until the street gets some visibility about the earnings impact of the Gilead price war on HCV drugs and the Humira copies hitting in 2017? Who knows? My opinion is that the shares will do the opposite of what the street thinks they will do. The weekly [...]
Conversions, Domestic corporations doing reverse mergers into foreign corporations, are becoming a key item in the corporate tax loop-hole bag of tricks. US corporate taxes are anti capital and prohibitive in doing domestic deals. This is a fact, and for you progressive tax parade marchers, stalled out growth puts the 80,000 Pfizer employees at risk. [...]
GILD gets the bad rap regarding HEP C that and HEP C this. Regardless, the SEC filing just released that a director bought 10,000 shares at $99.92. I have no idea what the financial situation of the director is, but no one on earth, even an insider, wants to take down a million dollar hook [...]
CNS science is on a major rebound. In the past five years the number of drugs being developed by large drugmakers for brain and nervous system disorders fell 50% to 129, according to NeuroPerspective. Some of the big drug companies, including Johnson & Johnson, Roche and Novartis are back in the brain labs . New [...]
Alkermes plc (ALKS) reported positive top-line data from a phase I study on its experimental multiple sclerosis (MS) drug, ALKS 8700. I'm always interested to see how the heads of finance explain a move in the markets. I'll let you guys in on a secret. News does not drive stocks. It never has and never [...]
Pfizer takes out Hospira for $90 a share. No biggie, what's another $15 1/2 billion of cash amongst friends? I guess a few billion here and a few billion there means nothing any more? A 39% premium? Pretty soon, we will have 1 remaining ginormous Pharma company who owns the entire space. I remember back in [...]
Glaxo weighs the benefits of spinning off ViiV once again. Everyone knows by now that I say it like it is so here it is: The only reason for the spin off, or at least the only reason that really matters, is to boost up the sucking performance of GSK shares. With flat to negative [...]
Typical of traders to rout the shares after another quarter of blow out numbers. Everyone knows the street is spooked easily. Gilead was not clear on the HEP C sales for 2015, so the unknown is a fail. Also, it looks like the discounting is double what it was in 2014. Another fail. I say [...]
